GNI Group ( ($JP:2160) ) just unveiled an update. GNI Group announced that its subsidiary Gyre Therapeutics has completed a Pre-New Drug ...

Shares of Gyre Therapeutics rose after the biopharmaceutical company's subsidiary reached alignment with regulators in China for conditional approval for its anti-fibrotic therapy Hydronidone. Shares ...

Datavault AI trades at elevated EV/sales and P/S multiples, leaving minimal margin for execution risk and relying on ...

Company finalizing preparations for end of January 2026 U.S. FDA Biologics License Application (BLA) submission for OST-HER2 ...

This normalization of mobile finance has important implications. Users are not experimenting with FinTech platforms on the ...

Gyre Pharmaceuticals completed a Pre-NDA meeting with China’s CDE, which agreed that the existing Phase 3 clinical data support a conditional ...

Wang noted that the indicator activates only on designated pilot sections, signaling that the vehicle meets the conditions ...